Onyx's (ONXX) Myeloma Drug Might be used for Earlier Stage Treatments
Tweet
Share
E-mailGet Alerts ONXX Hot Sheet
Price: $124.70 --0%
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Dr. Ravi Vij, associate professor at the department of Medicine at Washington University, told analyst Ling Wang of Summer Street that Kyprolis may eventually be used in the majority of his 3rd-line or higher patients. He is also hoping to use it in 2nd-line patients, assuming he doesn’t get pushback on reimbursement.
Vij doesn’t expect higher dose Kyprolis front-line use before official approval, but he has treated a dozen patients with Kyprolis over past two weeks. Initial patients treated tend to be heavily pretreated, 4th or 5th line patients.
Shares of Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) are higher by 70 percent year-to-day.
Vij doesn’t expect higher dose Kyprolis front-line use before official approval, but he has treated a dozen patients with Kyprolis over past two weeks. Initial patients treated tend to be heavily pretreated, 4th or 5th line patients.
Shares of Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) are higher by 70 percent year-to-day.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- DA Davidson Starts Everus (ECG) at Buy
- Cummins (CMI) PT Lowered to $675 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, General NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
